More than 1,600 Lipitor Lawsuits Now Included in South Carolina Litigation, Bernstein Liebhard LLP Reports
New York, NY (PRWEB) January 18, 2015 -- More than 100 new Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/ ) were filed over the past month in a federal litigation that continues to move forward in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports.
Court documents issued on January 15th, 2015 indicate that 1,604 cases involving the cholesterol-lowering statin medication have now been centralized in the proceeding, which includes claims that similarly allege the drug’s association with new-onset Type 2 diabetes. Since records were last updated in December 2014 to reflect 1,478 Lipitor lawsuits, more than 100 cases have been added to the multidistrict litigation (MDL) in South Carolina. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is not surprised to see federally-filed Lipitor lawsuits continuing to move forward in South Carolina, as we are investigating numerous cases on behalf of individuals who allegedly developed diabetes due to their use of Lipitor,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is currently offering free and confidential case evaluations to individuals who were diagnosed with Type 2 diabetes after taking Lipitor.
Lipitor Lawsuits
According to court documents, Lipitor lawsuits filed in South Carolina federal court allege that Pfizer Inc.’s labeling on the statin inadequately warns about its potential to cause Type 2 diabetes, even after it was adjusted in February 2012 at the request of the U.S. Food and Drug Administration (FDA). The health regulator issued a mandate at this time that all statin manufacturers adjust their products’ warning labels to note its association with the disease. The FDA notice followed the recently published results of a study in JAMA: Internal Medicine that found an increased risk of diabetes in post-menopausal women on statins.*
Women who were diagnosed with Type 2 diabetes following their use of Lipitor may be eligible to seek compensation for out-of-pocket medical expenses, lost wages and other injury-related damages. Learn more about the alleged association between Lipitor and diabetes when you visit Bernstein Liebhard LLP’s website, or by calling the following toll-free number directly for a free and confidential case review: 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 23, 2012.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Lipitor Lawsuit Diabetes Information Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article